Streetbeat News

Stock Prices

ZVRA

Analysts have varied opinions on Zevra Therapeutics (NASDAQ:ZVRA), with most being bullish. Recent price targets average $19.71, up from $18.17. Despite positive analyst sentiment, Zevra faces financial challenges, including declining revenue and high debt.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 5:01 pm

CF

CF Industries Holdings (NYSE:CF) has received mixed analyst ratings over the past three months, with a trend towards more bullish perspectives. Analysts have set a 12-month average price target of $86.58, reflecting a 2.86% increase from the previous target. Despite a recent revenue decline, CF Industries maintains strong profitability and financial health, though it carries a higher debt-to-equity ratio than industry averages.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 5:00 pm

PRI

Primerica (NYSE:PRI) has significantly outperformed the market over the past decade, with an average annual return of 18.5%, surpassing the market by 7.27% annually. A $1000 investment in PRI 10 years ago would now be worth $5,399.18.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 5:00 pm

EH

EHang shares rose following the successful completion of its first EH216-S pilotless eVTOL flight in Brazil, marking a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 5:00 pm

SNPS

Synopsys (NASDAQ:SNPS) has significantly outperformed the market over the past 20 years, with an annualized return of 18.66%. A $1000 investment in SNPS 20 years ago would be worth $32,172.59 today. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 5:00 pm

CFG

CSCO

IYR

PYPL

The CNBC Halftime Report highlighted final trades including PayPal Holdings, Cisco Systems, Citizens Financial Group, and the iShares U.S. Real Estate ETF. These assets were discussed as potential investment opportunities.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 5:00 pm

HUMA

A significant options activity was observed for Humacyte (HUMA) with a sweep of 30 call options for the October 18 expiration at a strike price of $7.5, priced near the ask at $0.201. This is notable given the open interest of 4796 and the upcoming earnings report on November 7.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:55 pm

NVO

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, discussed with the U.S. Congress the high prices of their weight loss drugs, Ozempic and Wegovy, in the U.S. compared to other countries. He expressed willingness to explore ways to make these drugs more affordable in the U.S., following commitments from pharmacy benefit managers to maintain coverage if prices are reduced.

Portfolio Pulse from Michael Juliano

September 24, 2024 | 4:53 pm

MPLN

MultiPlan shares declined following Citigroup's decision to lower its price target from $17.2 to $10.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:52 pm

MULN

Mullen Automotive shares are experiencing a decline following an update from the CEO regarding sales growth, financing, and new vehicle orders.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:47 pm